Cover Image
市場調查報告書

視神經病變 : 開發中產品分析

Optic Neuropathy - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 257807
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
視神經病變 : 開發中產品分析 Optic Neuropathy - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 57 Pages
簡介

所謂視神經病變是先天性視覺障礙的一種,主要的症狀為眼睛疼痛和不舒服,發麻,刺痛,視覺朦朧等。易罹病素質包含年齡和抽煙、酒精、抗癌劑、化學藥品相關壓力,部分抗生素、氰基等。

本報告提供全球各國治療視神經病變所用的開發中產品之開發情形相關分析,提供開發中產品之開發·上市最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

視神經病變概要

治療藥的開發

  • 視神經病變開發中產品:概要
  • 企業所開發的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

視神經病變:治療藥的評估

  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

視神經病變開發治療藥的企業

  • Amgen Inc
  • BioAxone BioSciences Inc
  • Inotek Pharmaceuticals Corp
  • Ironwood Pharmaceuticals Inc
  • PharmatrophiX Inc
  • Quark Pharmaceuticals Inc
  • Regenera Pharma Ltd

藥物簡介

視神經病變治療藥:開發暫停的產品

視神經病變相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9666IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H2 2017, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Optic Neuropathy - Overview
    • Optic Neuropathy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Optic Neuropathy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Optic Neuropathy - Companies Involved in Therapeutics Development
    • Amgen Inc
    • BioAxone BioSciences Inc
    • Ironwood Pharmaceuticals Inc
    • Quark Pharmaceuticals Inc
    • Regenera Pharma Ltd
    • Regeneron Pharmaceuticals Inc
  • Optic Neuropathy - Drug Profiles
      x
    • aflibercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BA-240 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IWP-953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-22A4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPI-1007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPh-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Optic Neuropathy - Dormant Projects
  • Optic Neuropathy - Discontinued Products
  • Optic Neuropathy - Product Development Milestones
    • Featured News & Press Releases
      • Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on 'Stroke of the Eye'
      • Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007
      • Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
      • Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
      • Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
      • Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
      • Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
      • Sep 18, 2012: Neurotech Pharmaceuticals Provides Update On NT-501
      • Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Optic Neuropathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Optic Neuropathy - Pipeline by Amgen Inc, H2 2017
  • Optic Neuropathy - Pipeline by BioAxone BioSciences Inc, H2 2017
  • Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
  • Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H2 2017
  • Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H2 2017
  • Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Optic Neuropathy - Dormant Projects, H2 2017
  • Optic Neuropathy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Optic Neuropathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top